Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

Targeting tumor's vulnerability yields durable responses in Phase I/II

Trial

SEATTLE, Nov. 21 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX), announced that cumulative preliminary results of a phase I trial combining cisplatin with brostallicin in patients with solid tumors that had relapsed or were resistant to front-line treatment were presented at the Highlights in Oncology meeting in Naples, Italy, on Tuesday, November 20, 2007. Cristina Geroni, Ph.D. of Nerviano Medical Sciences (NMS), which developed brostallicin, summarized the basis for the phase I trial design. The trial is based on data demonstrating tumors with high levels of GSH/GST, common in platinum-resistant disease, are more susceptible to the killing effects of brostallicin. High levels of GSH and GST are associated with resistance to most standard chemotherapy drugs

"Our phase I and II experience with brostallicin in over 160 patients demonstrates encouraging anti-tumor activity in a variety of solid tumors, with more than 50% of the patients experiencing at least disease stabilization," said Steven Weitman, M.D., of Systems Medicine.

The preliminary results from the first 21 patients treated in the phase I combination trial with cisplatin showed similar results, with 14 of the patients experiencing stable disease and half (50%) of those 14 patients having durable stable disease for more than six cycles of therapy. Toxicities were mainly hematological and were manageable and reversible in this heavily pretreated patient population. Phase II studies using this combination in patients resistant to standard therapy are planned.

About the Phase I Study

The phase I, multicenter, dose-escalation study of brostallicin in combination with cisplatin (cDDP) was conducted in patients with recurrent or metastatic solid tumors. Treatment cycles wer
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...Nov. 5 The endangered black-footed...U.S. This rare carnivore feeds on prairie dogs. ...nd often entire population die-offs in towns occur...implemented a ferret breeding program and has been...merly native habitat. Unfortunately, plague can s...
(Date:11/5/2009)...if., Nov. 5 ThermoGenesi...novative products for processing and storing adult...quarter of fiscal 2010. ,, For the quarter ende...s of $5.2 million, a 15 percent increase over reve...go. The Company said the key contributors to the g...
(Date:11/5/2009).... 5 BioSpecifics Technol...company developing first-in-class collagenase-base...for the third quarter ended September 30, 2009. ,...f this year, the FDA,s Arthritis Advisory Committe...approval of XIAFLEX(TM) for the treatment of Dupuy...
(Date:11/5/2009)...mber 5, 2009 Senomyx, In...oprietary taste receptor-based technologies to dis...age, and ingredient supply industries, today provi...lts for the third quarter ended September 30, 2009...r of 2009, compared to $4.0 million for the third ...
Breaking Biology Technology:Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...DNA polymerase for robust, high-fidelity PCR,amp... Nielson Valerie,Hedden Connie Hansen Janice ...k Madden ,Stratagene , Stratagene announces th...roved version of Pfu DNA polymerase for high-fide...cloned Pfu DNA,polymerase and a novel thermostab...
... , Novel Herculase Hotstart DNA polymeras... ,, , Michael Borns...ene ,, Stratagenes Herculase , ... enzyme for difficult PCR applications, particula...copy number, or GC-rich templates. We have expande...
... and native eukaryotic amino acid sequence , ,...ems, Inc. , The ESP LIC cloning and expression s...f recombinant proteins in yeast. This system uses,... and directional cloning of PCR,products immedia...GST),purification tag and the recognition site f...
Other Biology Technology:Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 2Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 3Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 4Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 5Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 6Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 7Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 8Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 9Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 10Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 11The Best Enzyme for the Toughest PCR Challenges Improved with New Hot-Start Feature 2The Best Enzyme for the Toughest PCR Challenges Improved with New Hot-Start Feature 3New Yeast Cloning System for Producing Proteins with Native Amino Acid,Sequences 2New Yeast Cloning System for Producing Proteins with Native Amino Acid,Sequences 3New Yeast Cloning System for Producing Proteins with Native Amino Acid,Sequences 4New Yeast Cloning System for Producing Proteins with Native Amino Acid,Sequences 5
(Date:11/5/2009)...hers (NABT) will recognize Leonard C. Yannielli, p...y Community College (NVCC) in Waterbury, Connectic... the NABT annual professional development conferen...ado. , The Evolution Education Award is cosponso...es,(AIBS) and Biological Sciences Curriculum Stud...
(Date:11/4/2009)... Long Beach and Riverside are responsible for a si...ma, and the true impact of air pollution and ship ...mated, according to researchers at the University ...h appears in an online edition of the American Jo...nt of all childhood asthma cases in Long Beach and...
(Date:11/4/2009)...ewswire/ -- Spectros, developer and manufacturer o...hich shed light on life-threatening diseases, anno...ion deals for both its T-Stat® VLS Tissue Oxi...stralia, New Zealand, The Netherlands, Belgium, L...n, Portugal, Poland, Greece, Turkey, and Russia. ...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2USC study finds big air pollution impacts on local communities 2Spectros Signs New International Distribution Deals 2Imagenetix Inc Reports Year End Results 49281 1Imagenetix Inc Reports Year End Results 49281 2Imagenetix Inc Reports Year End Results 49281 3Imagenetix Inc Reports Year End Results 49281 4Imagenetix Inc Reports Year End Results 49281 5Chiltern Expands European Operations With a New Office in Belgium 49279 1Chiltern Expands European Operations With a New Office in Belgium 49279 2Health Care Service Corporation Names Carolyn H Clift as Senior Vice President and First Chief Diversity Officer 49277 1Health Care Service Corporation Names Carolyn H Clift as Senior Vice President and First Chief Diversity Officer 49277 2
...n experimental RNA-based drug -- the first of its ...and then springs into action to destroy them, whil...oped at Duke University Medical Center, uses one t...enter cancer cells, and another type, called silen... keeps the cells alive. , In tests in mice with ...
... through a laboratory version of boot camp may hel...niversity of Pittsburgh researchers. In essence, t...l therapeutic vaccine loaded with a patient,s own ...zed to rally other cells of the immune system in f... the XVI International AIDS Conference (AIDS 2006)...
...t of Ophthalmology,s Schepens Eye Research Institu...are the first to learn why the cornea, the clear w...ue phenomenon that makes vision possible. The key,...f large amounts of the protein VEGFR-3 (vascular e...ithelial layer of normal healthy corneas. Accordin...
Other Biology News:Experimental RNA-based drug kills prostate cancer cells effectively and safely 2T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 2T cells activated to fight HIV basis for dendritic cell therapeutic vaccine 3Scientists discover why cornea is transparent and free of blood vessels, allowing vision 2Scientists discover why cornea is transparent and free of blood vessels, allowing vision 3
Silencer Pre-designed siRNA, PAGE purified, annealed from Ambion
...are designed to rapidly and reliably amplify unkno... APAgene provides hassle-free, ready-to use compon... necessary ingredients are provided in each kit. T...t-end amplification of large clones such as P1, YA...
Rabbit Anti-Yaf9 Polyclonal Antibody, Unconjugated from Abcam
...is designed to deparaffinize and perform Heat Indu...affin-embedded tissue sections mounted on glass mi...by melting the paraffin at the high temperature us...ation of the paraffin by detergent. Formaldehyde f...
Biology Products: